{'url': 'https://finance.yahoo.com/sectors/healthcare/', 'id': 116, 'text': '\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nHealthcare Stock Performance - Yahoo Finance \n\n\n\n              News  Today\'s news   US   Politics   World   Tech  Reviews and deals  Audio  Computing  Gaming  Health  Home  Phones  Science  TVs     Climate change   Health   Science   Originals  The 360     Newsletters    Life  Health  COVID-19  Fall allergies  Health news  Mental health  Relax  Sexual health  Studies  The Unwind     Parenting  Family health  So mini ways     Style and beauty  It Figures  Unapologetically     Horoscopes   Shopping  Buying guides     Food   Travel   Autos   Gift ideas   Buying guides    Entertainment  Celebrity   TV   Movies   Music   How to Watch   Interviews   Videos     Finance  My Portfolio   News  Latest News  Stock Market  Originals  The Morning Brief  Premium News     Economics  Housing  Earnings  Tech  Crypto  Biden Economy     Markets  Stocks: Most Actives  Stocks: Gainers  Stocks: Losers  Trending Tickers  Futures  World Indices  US Treasury Bonds Rates  Currencies  Crypto  Top ETFs  Top Mutual Funds  Options: Highest Open Interest  Options: Highest Implied Volatility  Sectors  Basic Materials  Communication Services  Consumer Cyclical  Consumer Defensive  Energy  Financial Services  Healthcare  Industrials  Real Estate  Technology  Utilities     Research  Screeners  Calendar  Stock Comparison  Advanced Chart  Currency Converter  Investment Ideas     Research Reports        Personal Finance  Credit Cards  Banking  Best HYSA  Student Loans  Personal Loans  Insurance  Mortgages  Mortgage Calculator  Taxes     Videos  Latest News  Editor\'s Picks  Investing Insights  Trending Stocks  All Shows  Morning Brief  Opening Bid  Wealth  Invest  ETF Report     Streaming Now    Sports  Fantasy  News  Fantasy football  Best Ball  Pro Pick \'Em  College Pick \'Em  Fantasy baseball  Fantasy hockey  Fantasy basketball  Download the app     Daily fantasy   NFL  News  Scores and schedules  Standings  Stats  Teams  Players  Drafts  Injuries  Odds  Super Bowl  GameChannel  Videos     MLB  News  Scores and schedules  Standings  Stats  Teams  Players  Odds  Videos  World Baseball Classic     NBA  News  Draft  Scores and schedules  Standings  Stats  Teams  Players  Injuries  Videos  Odds  Playoffs     NHL  News  Scores and schedules  Standings  Stats  Teams  Players  Odds  Playoffs     Soccer  News  Scores and schedules  Premier League  MLS  NWSL  Liga MX  CONCACAF League  Champions League  La Liga  Serie A  Bundesliga  Ligue 1  World Cup     College football  News  Scores and schedules  Standings  Rankings  Stats  Teams     Show all  MMA  WNBA  Sportsbook  NCAAF  Tennis  Golf  NASCAR  NCAAB  NCAAW  Boxing  USFL  Cycling  Motorsports  Olympics  Horse racing  GameChannel  Rivals  Newsletters  Podcasts  Videos  RSS  Jobs  Help  World Cup  More news     New on Yahoo Creators Games Tech    Terms  Privacy  Privacy Dashboard   Feedback   © 2024  All rights reserved.  About our ads  Advertising  Careers    Yahoo Finance                                    Yahoo Finance    Search query                  Select edition  USEnglish   US y LATAMEspañol  AustraliaEnglish  CanadaEnglish  CanadaFrançais  DeutschlandDeutsch  FranceFrançais  香港繁中  MalaysiaEnglish  New ZealandEnglish  SingaporeEnglish  台灣繁中  UKEnglish     News   Finance   Sports   More News Today\'s news  US  Politics  World  Weather  Climate change  Health  Science  Originals  Newsletters   Life Health  Parenting  Style and beauty  Horoscopes  Shopping  Food  Travel  Autos  Gift ideas  Buying guides   Entertainment Celebrity  TV  Movies  Music  How to watch  Interviews  Videos   Finance My portfolio  Watchlists  Markets  News  Videos  Screeners  Personal finance  Crypto  Industries   Sports Fantasy  NFL  NBA  MLB  NHL  College football  College basketball  Soccer  MMA  Yahoo Sports AM    New on Yahoo Creators Games Tech    Selected edition   USEnglish             Mail       Sign in       My Portfolio    News    Latest News Stock Market Originals The Morning Brief Premium News   Economics Housing Earnings Tech Crypto Biden Economy    Markets    Stocks: Most Actives Stocks: Gainers Stocks: Losers Trending Tickers Futures World Indices US Treasury Bonds Rates Currencies Crypto Top ETFs Top Mutual Funds Options: Highest Open Interest Options: Highest Implied Volatility Sectors Basic Materials Communication Services Consumer Cyclical Consumer Defensive Energy Financial Services Healthcare Industrials Real Estate Technology Utilities    Research    Screeners Calendar Stock Comparison Advanced Chart Currency Converter Investment Ideas   Research Reports      Personal Finance    Credit Cards Banking Best HYSA Student Loans Personal Loans Insurance Mortgages Mortgage Calculator Taxes    Videos    Latest News Editor\'s Picks Investing Insights Trending Stocks All Shows Morning Brief Opening Bid Wealth Invest ETF Report     Streaming Now    …  \n\n\n\n\nUpgrade to Premium\n\n       Overview   World Indices   Futures   Bonds   Currencies   Options   Sectors   Stocks   Crypto   ETFs   Mutual Funds       We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.        Sectors    / Healthcare   Healthcare This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies. Also include pharmaceutical retailers and companies which provide health information services. Companies in this sector include AstraZeneca, Pfizer, and Roche Holding, Walgreens Boots Alliance, and Cerner Corp.   Market Cap 6.273T  Market Weight 9.50%  Industries 11  Companies 1209   Healthcare  S&P 500 ^GSPC   1D    5D    1M    6M    YTD    1Y    5Y    All      Advanced Chart         Loading Chart for Healthcare   9/21 12:03 PM  DELL       Date  Close  Open  High  Low  Volume                 Day Return   Sector 0.35%  S&P 500 0.09%    YTD Return   Sector 0.89%  S&P 500 23.00%    1-Year Return   Sector 2.27%  S&P 500 23.76%    3-Year Return   Sector 6.73%  S&P 500 26.98%    5-Year Return   Sector 36.47%  S&P 500 82.14%   Note: Sector performance is calculated based on the previous closing price of all sector constituents    Industries in This Sector  Select an Industry for a Visual Breakdown  All Industries   All Industries  Drug Manufacturers - General  Medical Devices  Healthcare Plans  Biotechnology  Diagnostics & Research  Medical Instruments & Supplies  Medical Care Facilities  Drug Manufacturers - Specialty & Generic  Medical Distribution  Health Information Services  Pharmaceutical Retailers    IndustryMarket WeightYTD Return  All Industries  100.00% -0.89%  Drug Manufacturers - General  33.87% 3.97%  Medical Devices  13.06% 1.92%  Healthcare Plans  12.01% -17.05%  Biotechnology  11.17% -9.78%  Diagnostics & Research  11.08% -3.86%  Medical Instruments & Supplies  8.08% 20.90%  Medical Care Facilities  2.88% 5.46%  Drug Manufacturers - Specialty & Generic  2.87% -4.94%  Medical Distribution  2.53% 11.94%  Health Information Services  2.30% 12.06%  Pharmaceutical Retailers  0.14% -62.78%   Note: Percentage % data on heatmap indicates Day Return All Industries     --  Day Return --  Market Weight --  YTD Return --     Drug Manufacturers - General -0.24%   Medical Devices 0.27%   Healthcare Plans -1.28%   Biotechnology -1.50%   Diagnostics & Research 0.20%   Medical Instruments & Supplies -0.19%   Medical Care Facilities -0.14%   Drug Manufacturers - Specialty & Generic -0.78%   Medical Distribution 0.64%   Health Information Services 1.19%   Pharmaceutical Retailers -3.51%     <= -3   -2   -1   0   1   2   >= 3    Largest Companies in This Sector View More     table Table View   heatmap Heatmap View    Name  Last Price  1Y Target Est.  Market Weight  Market Cap  Day Change %  YTD Return  Avg. Analyst Rating      LLY  Eli Lilly and Company  757.54 999.43 11.07%  681.268B  -0.94%  +29.96% Buy     UNH  UnitedHealth Group Incorporated  489.25 625.10 7.31%  450.249B  -2.10%  -7.07% Buy     JNJ  Johnson & Johnson  143.58 175.98 5.62%  345.686B  -0.81%  -8.40% Buy     ABBV  AbbVie Inc.  171.52 208.90 4.92%  303.1B  -0.87%  +10.68% Buy     MRK  Merck & Co., Inc.  99.52 133.43 4.09%  251.75B  +1.20%  -8.71% Buy     TMO  Thermo Fisher Scientific Inc.  516.69 657.43 3.21%  197.634B  +0.10%  -2.66% Buy     ABT  Abbott Laboratories  112.42 130.24 3.17%  194.988B  +0.44%  +2.14% Buy     ISRG  Intuitive Surgical, Inc.  523.91 539.24 3.03%  186.606B  -0.49%  +55.30% Buy     DHR  Danaher Corporation  226.16 288.34 2.65%  163.35B  -0.94%  -2.24% Buy     PFE  Pfizer Inc.  25.77 32.62 2.37%  146.038B  -0.46%  -10.49% Buy      View More     Investing in the Healthcare Sector  Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds ETF Opportunities View More    Name  Last Price  Net Assets  Expense Ratio  YTD Return      XLV  SPDR Select Sector Fund - Healt  136.28 39.535B 0.09%  -0.07%    VHT  Vanguard Health Care ETF  250.81 20.562B 0.10%  +0.04%    XBI  SPDR Series Trust  SPDR S&P Bio  89.81 7.257B 0.35%  +0.58%    IBB  iShares Biotechnology ETF  131.21 6.968B 0.45%  -3.42%    IHI  iShares U.S. Medical Devices ET  57.93 4.768B 0.40%  +7.34%     View More    Mutual Fund Opportunities View More    Name  Last Price  Net Assets  Expense Ratio  YTD Return      VGHCX  Vanguard Specialized Portfolios  199.95 44.838B 0.30%  -4.38%    VGHAX  Vanguard Health Care Fund Admir  84.34 44.838B 0.30%  -4.34%    VHCIX  Vanguard HealthCare Index Fund   125.45 20.562B 0.10%  +0.02%    THISX  T. Rowe Price Health Sciences F  79.37 14.602B 0.80%  -9.93%    PRHSX  T. Rowe Price Health Sciences F  79.19 14.602B 0.80%  -9.91%     View More       Healthcare Research  View More    Discover the Latest Analyst and Technical Research for This Sector   Analyst Report: Vertex Pharmaceuticals Incorporated     Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.   Rating  Price Target    Morningstar• 11 hours ago  \xa0    Daily – Vickers Top Insider Picks for 12/19/2024     The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.  Argus• yesterday  \xa0    Analyst Report: Stryker Corporation     Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker\'s total revenue currently comes from outside the United States.   Rating  Price Target    Morningstar• yesterday  \xa0    Analyst Report: Waters Corporation     Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.    Rating  Price Target    Morningstar• yesterday  \xa0    View More    From the Community     Healthcare News    All    News    Press Releases       FDA finalizes decision to end Lilly\'s GLP-1 shortage, analysts predict Novo will be next The FDA decided the shortage for Eli Lilly\'s GLP-1 tirzepatide has finally come to an end.   Yahoo Finance • 15 hours ago   NONOF   0.00%   NVO   -2.38%   HIMS   -7.67%       InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), investigating the Company’s oral C5aR inhibitor, INF904. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: “We are pleased to have started our Phase   GlobeNewswire • 3 minutes ago   IFRX   -1.39%        Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it plans to effectuate a strategic reorganization effective on December 20, 2024. This reorganization will include changing the Company’s name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. After this reorganization, the Company will continue to trad   GlobeNewswire • 3 minutes ago   ELAB   +9.30%       FDA Approves Ionis Pharmaceuticals\' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (SHTG) that can lead to acute pancreatitis (AP). SHTG is a condition where the level of triglycerides (type of fat) in the blood is more than three times the normal level. Tryngolza is the first-ever FDA-approved treatment that significantly and subs   Benzinga • 9 minutes ago   IONS   -1.82%       B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data B. Riley analyst Mayank Mamtani upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a price target of $1.50, up from $1. The company’s topline results from the Phase 2 SHIMMER study of CT1812 in patients with dementia with Lewy bodies exceeded expectations in terms of consistency and magnitude of treatment effect, the analyst tells investors in a research note. The firm says Cognition is “here to stay, even thrive now” on the back of these results. Published first on TheFly – the ult   TipRanks • 12 minutes ago   CGTX   +9.31%       Guggenheim sees Neogen ‘turning the corner,’ starts with a Buy As previously reported, Guggenheim initiated coverage of Neogen (NEOG) with a Buy rating and $15 price target Neogen is a “leading” pure-play food safety testing company with 20% market share of the global market, the analyst noted. While the company has struggled with integration issues subsequent to the acquisition of the 3M Food Safety business and “challenges linger,” which continues to affect growth and margins, the firm believes the company is progressing towards turning the corner and vie   TipRanks • 12 minutes ago   NEOG   +3.26%       CorMedix price target raised to $12 from $11 at RBC Capital RBC Capital raised the firm’s price target on CorMedix (CRMD) to $12 from $11 and keeps an Outperform rating on the shares. The company has had a productive 2024 with the launch of DefenCath ongoing, and the management has remained in execution mode, establishing commercial agreements with dialysis providers and operators, including the signing of a large dialysis organization, the analyst tells investors in a research note. As DefenCath’s launch matures, RBC sees signs of reduced ordering and l   TipRanks • 12 minutes ago   CRMD   +9.24%       Immunovant price target lowered to $45 from $47 at Wells Fargo Wells Fargo analyst Derek Archila lowered the firm’s price target on Immunovant (IMVT) to $45 from $47 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks   TipRanks • 13 minutes ago   IMVT   -2.25%        Incyte price target raised to $70 from $68 at Wells Fargo Wells Fargo raised the firm’s price target on Incyte (INCY) to $70 from $68 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRa   TipRanks • 13 minutes ago   INCY   -0.73%       iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo Wells Fargo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $19 from $31 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended b   TipRanks • 13 minutes ago   ITOS   -0.55%       Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China\'s National Medical Products Administration Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China\'s National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), f   PR Newswire • 13 minutes ago   IVBIY   0.00%   IVBXF   0.00%   NUVB   +3.07%          Is There An Opportunity With ProQR Therapeutics N.V.\'s (NASDAQ:PRQR) 37% Undervaluation? Key Insights Using the 2 Stage Free Cash Flow to Equity, ProQR Therapeutics fair value estimate is US$4.13 ProQR...   Simply Wall St. • 14 minutes ago   PRQR   +0.78%       Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now? We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other cheap NYSE stocks to invest in now. The stock market appears poised for another year of impressive returns, likely extending into 2025. However, […]   Insider Monkey • 14 minutes ago   PFE   -0.46%       5 Things to Know Before the Stock Market Opens News of the day for Dec. 20, 2024   Investopedia • 15 minutes ago   FDX   +1.00%   NVO   -2.38%        Clearside announces publication of insights on drug development, regulation Clearside Biomedical (CLSD) announced that the official journal of The Royal College of Ophthalmologists, Eye, published a summary of critical insights into drug development and regulatory processes based on a presentation at the prestigious annual Edridge Green Lecture by Clearside’s Chief Medical Officer and Executive Vice President, Head of Research and Development, Dr. Victor Chong. The article, which was published in December 2024 by Eye and Nature.com, provides a comprehensive overview of   TipRanks • 17 minutes ago   CLSD   -4.12%       Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025. On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026. Preclinical data   TipRanks • 18 minutes ago   ORKA   -2.72%       Armata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study Armata Pharmaceuticals (ARMP) announced “encouraging” topline results from its Phase 2 trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa – P.a. or P. aeruginosa – infections in non-cystic fibrosis bronchiectasis, or NCFB, patients. The study evaluated the safety, pharmacokinetics and efficacy of inhaled AP-PA02. The primary efficacy endpoint was the reduction in P.a. colony forming units, or CFUs, in the lung sputum a   TipRanks • 18 minutes ago   ARMP   +1.54%       Maravai Lifesciences initiated with a Neutral at Guggenheim Guggenheim initiated coverage of Maravai Lifesciences (MRVI) with a Neutral rating as the firm expands its bioprocessing tools coverage. Maravai is a leading pure-play in mRNA capping and viral clearance assessment and while the current valuation likely limits downside, the firm’s Neutral view is based on its call that there are “more attractive categories within the bioprocessing subsegment.” Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. T   TipRanks • 18 minutes ago   MRVI   -2.69%       Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now? We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other cheap NYSE stocks to invest in now. The stock market appears poised for another year of impressive returns, likely extending into […]   Insider Monkey • 21 minutes ago   MRK   +1.20%       Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump. Novo Nordisk stock crashed Friday after the Danish giant reported its experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking Therapeutics jumped   Investor\'s Business Daily • 30 minutes ago   AMGN   +0.93%   NONOF   0.00%   NVO   -2.38%                 Copyright © 2024 Yahoo. All rights reserved.     POPULAR QUOTES Dow Jones   S&P 500   DAX Index   Nvidia   Tesla   DJT    EXPLORE MORE Mortgages   Credit Cards   Sectors   Crypto Heatmap   Biden Economy   Financial News    ABOUT Data Disclaimer   Help   Feedback   Sitemap   Licensing    What\'s New   About Our Ads    Premium Plans   Terms   and Privacy Policy    Privacy Dashboard                  U.S. markets open in 1h 57m     US    Europe    Asia    Rates    Commodities    Currencies    Cryptocurrencies      S&P Futures   5,804.00 -64.75 (-1.10%)            Dow Futures   42,082.00 -276.00 (-0.65%)            Nasdaq Futures   20,756.50 -356.25 (-1.69%)            Russell 2000 Futures   2,216.90 -28.50 (-1.27%)            Crude Oil   68.75 -0.63 (-0.91%)            Gold   2,620.20 +12.10 (+0.46%)                     My Portfolios    My Portfolios    Sign in to access your portfolio Sign in       Top Gainers       DRI Darden Restaurants, Inc. 183.44 +23.57 (+14.74%)             OKLO Oklo Inc. 20.96 +2.58 (+14.04%)             LZRFY Localiza Rent a Car S.A. 5.25 +0.48 (+10.06%)             VKTX Viking Therapeutics, Inc. 41.49 +3.21 (+8.39%)             SMMT Summit Therapeutics Inc. 18.40 +1.42 (+8.36%)               Top Losers       RGTI Rigetti Computing, Inc. 7.47 -3.22 (-30.12%)             LW Lamb Weston Holdings, Inc. 62.50 -15.72 (-20.10%)             MU Micron Technology, Inc. 87.09 -16.81 (-16.18%)             VRTX Vertex Pharmaceuticals Incorporated 396.64 -50.86 (-11.37%)             AI C3.ai, Inc. 35.45 -4.24 (-10.68%)               Most Active       NVDA NVIDIA Corporation 130.68 +1.77 (+1.37%)             RGTI Rigetti Computing, Inc. 7.47 -3.22 (-30.12%)             SOUN SoundHound AI, Inc. 18.86 -1.99 (-9.55%)             TSLA Tesla, Inc. 436.17 -3.96 (-0.90%)             PLTR Palantir Technologies Inc. 74.21 +2.70 (+3.78%)               Trending Tickers       NVO Novo Nordisk A/S 103.44 -2.52 (-2.38%)             LLY Eli Lilly and Company 757.54 -7.17 (-0.94%)             NOVO-B.CO Novo Nordisk A/S 619.60 -123.60 (-16.63%)             NKE NIKE, Inc. 77.10 +0.20 (+0.26%)             BTC-USD Bitcoin USD 93,519.90 -8,753.05 (-8.56%)               Top Economic Events    Top Economic Events    United States       Core PCE Price Index YY*  Dec 20, 2024, 8:30 AM EST Prior: P: 2.8 New: N: -   Core PCE Price Index YY*  Prior: 2.8 New: -    Core PCE Price Index YY*  Dec 20, 2024, 8:30 AM EST Prior: Prior: 2.8 New: New: -     PCE Price Index YY *  Dec 20, 2024, 8:30 AM EST Prior: P: 2.3 New: N: -   PCE Price Index YY *  Prior: 2.3 New: -    PCE Price Index YY *  Dec 20, 2024, 8:30 AM EST Prior: Prior: 2.3 New: New: -     Core PCE Price Index MM *  Dec 20, 2024, 8:30 AM EST Prior: P: 0.3 New: N: -   Core PCE Price Index MM *  Prior: 0.3 New: -    Core PCE Price Index MM *  Dec 20, 2024, 8:30 AM EST Prior: Prior: 0.3 New: New: -     Dallas Fed PCE*  Dec 20, 2024, 9:00 AM EST Prior: P: 2.3 New: N: -   Dallas Fed PCE*  Prior: 2.3 New: -    Dallas Fed PCE*  Dec 20, 2024, 9:00 AM EST Prior: Prior: 2.3 New: New: -              Terms   and Privacy Policy    Privacy Dashboard   Ad Terms   Feedback            \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n'}